利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

221 条记录 (耗时 0.032 秒)

    COMBINATION THERAPY OF A T CELL THERAPY AND A BTK INHIBITOR
    2.
    发明申请
    COMBINATION THERAPY OF A T CELL THERAPY AND A BTK INHIBITOR 审中-公开

    公开(公告)号：WO2018085731A3

    公开(公告)日：2018-07-12

    申请号：PCT/US2017060060

    申请日：2017-11-03

    申请人： JUNO THERAPEUTICS INC

    发明人： PORTS MICHAEL ,  SALMON RUTH ,  QIN JIM ,  BATUREVYCH OLEKSANDR ,  GILLENWATER HEIDI

    IPC分类号： A61K39/00 ,  A61K31/00 ,  A61K35/17 ,  C12N5/0783

    CPC分类号： A61K39/0011 ,  A61K31/00 ,  A61K35/17 ,  A61K2039/5156 ,  A61K2039/5158 ,  C12N5/0636 ,  C12N2501/599 ,  C12N2501/727 ,  C12N2510/00

    摘要： Provided herein are methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and inhibitors of a TEK family kinase, such as BTK or ITK. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more such inhibitor in conjunction with another agent, such as an immunotherapeutic agent targeting T cells, such as a therapeutic antibody, e.g., a multispecific (e.g., T cell engaging) antibody, and/or genetically engineered T cells, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are methods of manufacturing engineered T cells, compositions, methods of administration to subjects, nucleic acids, articles of manufacture and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, efficacy, persistence, expansion and/or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents.

    IMMUNE CELL COMPOSITIONS AND METHODS OF USING SAME
    3.
    发明申请
    IMMUNE CELL COMPOSITIONS AND METHODS OF USING SAME 审中-公开
    免疫细胞组合物及其使用方法

    公开(公告)号：WO2017100428A1

    公开(公告)日：2017-06-15

    申请号：PCT/US2016/065578

    申请日：2016-12-08

    申请人： MEMORIAL SLOAN KETTERING CANCER CENTER

    发明人： ADUSUMILLI, Prasad, S.

    IPC分类号： C12N5/0783 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0781

    CPC分类号： A61K35/17 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K2319/00 ,  C07K2319/03 ,  C12N5/0637 ,  C12N2501/505 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2510/00

    摘要： Disclosed herein are cells that are immunoinhibitory cell, which cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the cell. In certain embodiments, the immunoinhibitory cell is a regulatory T cell. In another aspect, provided herein is a regulatory T cell that recombinantly expresses a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response. The cells can be sensitized to an antigen that is the target of a pathologic immune response associated with an immune-mediated disorder. Additionally provided are methods of using such cells to treat an immune-mediated disorder in a subject in need thereof.

    摘要翻译： 本文公开了作为免疫抑制性细胞的细胞，所述细胞重组表达细胞介导的细胞免疫应答抑制剂的显性失活形式。 在某些实施方案中，免疫抑制性细胞是调节性T细胞。 另一方面，本文提供了调节性T细胞，其重组表达调节性T细胞介导的免疫应答抑制剂的显性失活形式。 细胞可以对作为与免疫介导的病症相关的病理性免疫应答的靶标的抗原敏化。 另外提供了在有此需要的受试者中使用此类细胞治疗免疫介导的病症的方法。

    HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3
    4.
    发明申请
    HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3 审中-公开
    人类抗体或其特异性片段

    公开(公告)号：WO2016180721A1

    公开(公告)日：2016-11-17

    申请号：PCT/EP2016/060148

    申请日：2016-05-06

    申请人： MILTENYI BIOTEC GMBH

    发明人： NÖLLE, Volker ,  THIE, Holger ,  KAISER, Andrew

    IPC分类号： C07K16/28 ,  C12N5/0783

    CPC分类号： C07K16/2809 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92 ,  C07K2317/94 ,  C12N5/0636 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599

    摘要： The present invention provides a humanized antibody or fragment thereof specific for the antigen CD3, wherein said antibody or fragment thereof comprises a heavy chain variable domain comprising a CDR1 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. In addition, the present invention provides a method for polyclonal stimulation of T cells comprising contacting a population of T cells with said anti-CD3 antibody, optionally with an anti-CD28 antibody, wherein said anti-CD3 antibody and optionally said anti-CD28 antibody are linked to particles. Further said anti-CD3 antibody can be used for reversible tagging of cells.

    摘要翻译： 本发明提供对抗原CD3特异性的人源化抗体或其片段，其中所述抗体或其片段包含包含SEQ ID NO：1的CDR1区，SEQ ID NO：2的CDR2区和SEQ ID NO：2的重链可变结构域，和 SEQ ID NO：3的CDR3区和包含SEQ ID NO：4的CDR1区，SEQ ID NO：5的CDR2区和SEQ ID NO：6的CDR3区的轻链可变结构域。 此外，本发明提供了一种T细胞多克隆刺激的方法，其包括将T细胞群与所述抗-CD3抗体任选地与抗CD28抗体接触，其中所述抗CD3抗体和任选的所述抗-CD28抗体 与颗粒相连。 此外，所述抗CD3抗体可用于细胞的可逆标记。

    CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING ANTIGEN PRESENT BOTH ON IMMUNE CELLS AND PATHOLOGICAL CELLS
    8.
    发明申请
    CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING ANTIGEN PRESENT BOTH ON IMMUNE CELLS AND PATHOLOGICAL CELLS 审中-公开
    用于靶向免疫细胞和病理细胞上的抗原的免疫球蛋白的细胞

    公开(公告)号：WO2015121454A1

    公开(公告)日：2015-08-20

    申请号：PCT/EP2015/053162

    申请日：2015-02-13

    申请人： CELLECTIS

    发明人： DUCHATEAU, Philippe ,  POIROT, Laurent

    IPC分类号： C12N5/0783 ,  A61K35/14

    CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61P35/00 ,  A61P35/02 ,  C12N2501/599 ,  C12N2510/00 ,  Y02A50/463

    摘要： Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CSl or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.

    摘要翻译： 开发用于免疫治疗的遗传工程化免疫细胞的方法，其可以赋予靶向抗原标记的嵌合抗原受体，所述嵌合抗原受体通过编码基因编码的基因（例如CD38，CS1或CD70）是常见的病原体细胞和所述免疫细胞 所述标记物通过罕见的切割内切核酸酶如TALEN，Cas9或argonaute在所述免疫细胞中灭活。

    METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY
    9.
    发明申请
    METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY 审中-公开
    用于工程用于免疫印迹的全血和高活性T细胞的方法

    公开(公告)号：WO2014184741A1

    公开(公告)日：2014-11-20

    申请号：PCT/IB2014/061409

    申请日：2014-05-13

    申请人： CELLECTIS

    发明人： GALETTO, Roman ,  GOUBLE, Agnes ,  GROSSE, Stephanie ,  MANNIOUI, Cecile ,  POIROT, Laurent ,  SCHARENBERG, Andrew ,  SMITH, Julianne

    IPC分类号： C12N5/0783 ,  C07K16/28 ,  C07K14/735

    CPC分类号： A61K35/17 ,  C07K14/7051 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/00 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99

    摘要： The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

    摘要翻译： 本发明涉及用于开发非同种异体反应的用于免疫治疗的工程化T细胞的方法。 本发明涉及通过使编码T细胞受体的两个基因和免疫检查点基因失活来释放免疫应答的潜力来修饰T细胞的方法。 该方法包括使用特异性稀有切割核酸内切酶，特别是TALE-核酸酶（TAL效应子内切核酸酶）和编码这种多肽的多核苷酸，以精确地靶向T细胞中的关键基因的选择，其可从供体或从原代培养获得 细胞。 本发明打开了治疗癌症和病毒感染的标准和负担得起的过继免疫治疗策略的方法。